IKT - Inhibikase Therapeutics GAAP EPS of -$0.16 in-line revenue of $0.06M

2023-05-15 16:01:34 ET

• Inhibikase Therapeutics press release ( NASDAQ: IKT ): Q1 GAAP EPS of -$0.16 in-line.
• Revenue of $0.06M (+20.0% Y/Y).
• R&D Expenses: Research and development expenses were $2.9 million for the quarter ended March 31, 2023 compared to $3.0 million in the quarter ended March 31, 2022. The decrease was primarily due to the company restarting its Phase 2 '201' clinical trial.

• SG&A Expenses: Selling, general and administrative expenses for the quarter ended March 31, 2023 were $1.9 million compared to $1.7 million for the quarter ended March 31, 2022. The increase was primarily the result of legal, consulting fees and promotional related costs.

• Cash Position: Cash and cash equivalents and marketable securities were $25.7 million as of March 31, 2023.

For further details see: